Olema Pharmaceuticals (OLMA) Filings

8-K

Regulation FD Disclosure

27 Sep 24

8-K

Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

6 Aug 24

8-K

Entry into a Material Definitive Agreement

2 Jul 24

8-K

Submission of Matters to a Vote of Security Holders

14 Jun 24

8-K

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

15 May 24

8-K

Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

8 May 24

ARS

2023 FY

Annual report to shareholders

26 Apr 24

DEFA14A

Additional proxy soliciting materials

26 Apr 24

S-8

Registration of securities for employees

11 Mar 24

8-K

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

11 Mar 24

424B3

Prospectus supplement

12 Feb 24

EFFECT

Notice of effectiveness

12 Feb 24

CORRESP

Correspondence with SEC

7 Feb 24

UPLOAD

Letter from SEC

7 Feb 24

S-3

Shelf registration

31 Jan 24

8-K

Olema Oncology JP Morgan Conference January 2024

8 Jan 24

8-K

Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

8 Jan 24

8-K

Entry into a Material Definitive Agreement

5 Jan 24

424B5

Prospectus supplement for primary offering

5 Jan 24

8-K

Regulation FD Disclosure

6 Dec 23

8-K

Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies

5 Dec 23

8-K

Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

7 Nov 23

8-K

Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant

23 Oct 23

8-K/A

Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors

18 Oct 23

8-K

Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors

17 Oct 23

8-K

Olema Oncology Announces Expansion of Collaboration

10 Oct 23

D

$130.00 mm in equity, sold $130.00 mm, 12 investors

14 Sep 23

8-K

Olema Oncology Announces Combined Financing for Up to $180 Million

5 Sep 23

8-K

Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update

8 Aug 23

8-K

Submission of Matters to a Vote of Security Holders

21 Jun 23

8-K

Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study

11 May 23

8-K

Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update

9 May 23

ARS

2022 FY

Annual report to shareholders

28 Apr 23

4

Senai Asefaw

5 Aug 24

4

Cyrus Harmon

31 Jul 24

144

Notice of proposed sale of securities

30 Jul 24

144

Notice of proposed sale of securities

29 Jul 24

4

Cyrus Harmon

12 Jul 24

144

Notice of proposed sale of securities

11 Jul 24

4

Cyrus Harmon

2 Jul 24

144

Notice of proposed sale of securities

28 Jun 24

4

MARK N LAMPERT

18 Jun 24

4

G. Walmsley Graham

18 Jun 24

4

Sandra Horning

18 Jun 24

4

ANDREW RAPPAPORT

18 Jun 24

4

Cyrus Harmon

18 Jun 24

4

Yi Larson

18 Jun 24

4

Gorjan Hrustanovic

18 Jun 24

4

IAN T CLARK

18 Jun 24

4

J. Scott Garland

18 Jun 24

4

CYNTHIA M BUTITTA

18 Jun 24

SC 13G

Point72 Asset Management, L.P.

14 Jun 24

SC 13D/A

Logos Global Management LP

6 Jun 24

4

G. Walmsley Graham

6 Jun 24

144

Notice of proposed sale of securities

6 Jun 24

144

Notice of proposed sale of securities

6 Jun 24

4

Cyrus Harmon

4 Jun 24

144

Notice of proposed sale of securities

4 Jun 24

144

Notice of proposed sale of securities

3 Jun 24

144

Notice of proposed sale of securities

31 May 24

4

Naseem Zojwalla

28 May 24

4

Cyrus Harmon

7 May 24

144

Notice of proposed sale of securities

6 May 24

4

Cyrus Harmon

2 May 24

144

Notice of proposed sale of securities

30 Apr 24

4

Cyrus Harmon

29 Mar 24

144

Notice of proposed sale of securities

28 Mar 24

SC 13G

Deep Track Capital, LP

22 Mar 24

4

Naseem Zojwalla

20 Mar 24

4

ANDREW RAPPAPORT

6 Mar 24

4

Cyrus Harmon

4 Mar 24

144

Notice of proposed sale of securities

29 Feb 24

SC 13G/A

Paradigm Biocapital Advisors LP

14 Feb 24